HCP1904-1

DRUG4 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyHypertension

Phase 1

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.

CompletedNCT05191563

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2021-07-31End: 2021-09-12Updated: 2022-01-13

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

CompletedNCT05407220

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2022-06-29End: 2022-07-25Updated: 2024-10-08

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

CompletedNCT05723549

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2023-02-02End: 2023-03-20Updated: 2023-09-22

Phase 3

Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

CompletedNCT04820907

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2020-10-27End: 2021-09-30Updated: 2023-09-22